Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc. (ODTC) Stock Overview
Explore Odonate Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
24.1B
P/E Ratio
8606.13
EPS (TTM)
$20580.00
ROE
0.07%
ODTC Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Odonate Therapeutics, Inc. (ODTC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $59124.42.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 8606.13 and a market capitalization of 24.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Kevin C. Tang
137
3 East 28th Street, New York City, NY
2017